Cargando…
A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES)
Patient: Female, 24-year-old Final Diagnosis: K2 induced posterior reversible encephalopathy syndrome Symptoms: Abnormal behavior • headache Medication: — Clinical Procedure: — Specialty: General and Internal Medicine • Toxicology OBJECTIVE: Unusual clinical course BACKGROUND: K2 is an artificially...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059105/ https://www.ncbi.nlm.nih.gov/pubmed/35470354 http://dx.doi.org/10.12659/AJCR.936209 |
_version_ | 1784698242534998016 |
---|---|
author | Ghazanfar, Haider Muthumanickam, Aruna Qureshi, Zaheer Altaf, Faryal Zeana, Cosmina Chilimuri, Sridhar |
author_facet | Ghazanfar, Haider Muthumanickam, Aruna Qureshi, Zaheer Altaf, Faryal Zeana, Cosmina Chilimuri, Sridhar |
author_sort | Ghazanfar, Haider |
collection | PubMed |
description | Patient: Female, 24-year-old Final Diagnosis: K2 induced posterior reversible encephalopathy syndrome Symptoms: Abnormal behavior • headache Medication: — Clinical Procedure: — Specialty: General and Internal Medicine • Toxicology OBJECTIVE: Unusual clinical course BACKGROUND: K2 is an artificially synthesized cannabinoid (SCB), manufactured as a non-consumption herbal incense but increasingly misused as a recreational drug. Posterior reversible encephalopathy syndrome (PRES) is a rare clinical and radiological entity characterized by brain edema, often in the setting of acute hypertension. Cases of PRES caused by recreational drug use have been reported in the literature. CASE REPORT: We report an unusual case of PRES after consumption of K2 in a 24-year-old healthy woman who presented with episodic agitation and altered mental status. Magnetic resonance imaging showed nonspecific subtle high T2/FLAIR (fluid-attenuated inversion recovery) signal intensities in the region of the posterior parietal and occipital cortices. Her extensive drug screen report was positive for K2. Her mental status improved over the course of 3 weeks and she had returned to her baseline at 3-month follow-up. CONCLUSIONS: Our case highlights the importance of having a high clinical suspicion in patients presenting with altered mental status and a history of recreational drug use. K2 is not detected by routine urine drug testing, so a high level of clinical suspicion is required to request an extensive drug screen. It is important for the physician to counsel active synthetic cannabinoid users regarding these rare complications. |
format | Online Article Text |
id | pubmed-9059105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90591052022-05-17 A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES) Ghazanfar, Haider Muthumanickam, Aruna Qureshi, Zaheer Altaf, Faryal Zeana, Cosmina Chilimuri, Sridhar Am J Case Rep Articles Patient: Female, 24-year-old Final Diagnosis: K2 induced posterior reversible encephalopathy syndrome Symptoms: Abnormal behavior • headache Medication: — Clinical Procedure: — Specialty: General and Internal Medicine • Toxicology OBJECTIVE: Unusual clinical course BACKGROUND: K2 is an artificially synthesized cannabinoid (SCB), manufactured as a non-consumption herbal incense but increasingly misused as a recreational drug. Posterior reversible encephalopathy syndrome (PRES) is a rare clinical and radiological entity characterized by brain edema, often in the setting of acute hypertension. Cases of PRES caused by recreational drug use have been reported in the literature. CASE REPORT: We report an unusual case of PRES after consumption of K2 in a 24-year-old healthy woman who presented with episodic agitation and altered mental status. Magnetic resonance imaging showed nonspecific subtle high T2/FLAIR (fluid-attenuated inversion recovery) signal intensities in the region of the posterior parietal and occipital cortices. Her extensive drug screen report was positive for K2. Her mental status improved over the course of 3 weeks and she had returned to her baseline at 3-month follow-up. CONCLUSIONS: Our case highlights the importance of having a high clinical suspicion in patients presenting with altered mental status and a history of recreational drug use. K2 is not detected by routine urine drug testing, so a high level of clinical suspicion is required to request an extensive drug screen. It is important for the physician to counsel active synthetic cannabinoid users regarding these rare complications. International Scientific Literature, Inc. 2022-04-26 /pmc/articles/PMC9059105/ /pubmed/35470354 http://dx.doi.org/10.12659/AJCR.936209 Text en © Am J Case Rep, 2022 https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Articles Ghazanfar, Haider Muthumanickam, Aruna Qureshi, Zaheer Altaf, Faryal Zeana, Cosmina Chilimuri, Sridhar A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES) |
title | A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES) |
title_full | A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES) |
title_fullStr | A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES) |
title_full_unstemmed | A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES) |
title_short | A Case of Synthetic Cannabinoid (K2)-Induced Posterior Reversible Encephalopathy Syndrome (PRES) |
title_sort | case of synthetic cannabinoid (k2)-induced posterior reversible encephalopathy syndrome (pres) |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059105/ https://www.ncbi.nlm.nih.gov/pubmed/35470354 http://dx.doi.org/10.12659/AJCR.936209 |
work_keys_str_mv | AT ghazanfarhaider acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres AT muthumanickamaruna acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres AT qureshizaheer acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres AT altaffaryal acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres AT zeanacosmina acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres AT chilimurisridhar acaseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres AT ghazanfarhaider caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres AT muthumanickamaruna caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres AT qureshizaheer caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres AT altaffaryal caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres AT zeanacosmina caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres AT chilimurisridhar caseofsyntheticcannabinoidk2inducedposteriorreversibleencephalopathysyndromepres |